Among the 244 HER2-negative breast cancer patients, HER2-ultralow tumors showed significantly higher ER positivity compared with HER2-null tumors (51.8% vs. 19.6%, p < 0.001), and also tended to show higher PgR positivity (p = 0.048). The gene discussed is ESR1; the disease is breast carcinoma.